ATRA Stock Crash: FDA Rejection Shocks Atara Biotherapeutics | What Now?
Автор: Stock or Twist
Загружено: 2026-01-12
Просмотров: 162
Описание:
Atara Biotherapeutics (ATRA) stock has crashed nearly 60% after receiving a second FDA Complete Response Letter for its lead cancer therapy, EBVALLO. Despite resolving previous manufacturing issues, the FDA has raised unexpected concerns about clinical trial design, leaving investors in a state of panic.
In this deep dive, we break down the latest news, Atara's precarious financial position, and the potential path forward through upcoming regulatory meetings. We also explore bull and bear case scenarios for the next 5 years to see if there is any hope for a recovery.
Key topics covered:
The details of the FDA's second CRL for EBVALLO
Business model and the Pierre Fabre partnership
Financial health and 90% headcount reduction
Price targets and investment strategies
#ATRA #AtaraBiotherapeutics #StockMarket #Biotech #Investing #StockOrTwist #FDA
This video is provided purely for entertainment purposes and does not constitute financial advice, as investing involves significant risk and the potential for total loss.
Повторяем попытку...
Доступные форматы для скачивания:
Скачать видео
-
Информация по загрузке:
